Rhenium re-186

DB19266InvestigationalSmall molecule

Rhenium re-186 is under investigation in clinical trial NCT01906385 (Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (Respect)).

Mechanism: Pharmacologically active on Chondroitin sulfate proteoglycan 4
Curator reviewed
Formula / weight: Re · 185.955 g/mol (avg)
Also known as: Rhenium (186-re) · Rhenium-186

Resolves to

Compound

UNIIZU7F1ET6TMCAS14998-63-1

Structure

InChIKeyWUAPFZMCVAUBPE-IGMARMGPSA-NSMILES[186Re]

Targets

Q6UVK1CSPG4

What you can answer from here — as of September 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Rhenium re-186, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account